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Osteoarthritis (OA) is the most common age-related rheumatic disease. Chondrocytes play a primary role in
mediating cartilage destruction and extracellular matrix (ECM) breakdown, which are main features of the
OA joint. Quantitative proteomics technologies are demonstrating a very interesting power for studying the
molecular effects of some drugs currently used to treat OA patients, such as chondroitin sulfate (CS) and
glucosamine (GlcN). In this work, we employed the iTRAQ (isobaric tags for relative and absolute
quantitation) technique to assess the effect of CS and GlcN, both alone and in combination, in modifying
cartilage ECM metabolism by the analysis of OA chondrocytes secretome. 186 different proteins secreted by
the treated OA chondrocytes were identified. 36 of them presented statistically significant differences (p #
0.05) between untreated and treated samples: 32 were increased and 4 decreased. The synergistic
chondroprotective effect of CS and GlcN, firstly reported by our group at the intracellular level, is now
demonstrated also at the extracellular level.
O
steoarthritis (OA) is the most common form of arthritis, mainly characterized by cartilage destruction.
Despite the increasing number of OA patients, no cure for this disease has been found to date. The
therapies currently available primarily address the handling of joint pain. The failure of conventional
treatments (analgesics or non-steroidal anti-inflammatory drugs) to regenerate or slow the degeneration of
damaged cartilage, combined with their frequent adverse side effects, may explain the increasing use of
SYSADOA (SYmptomatic Slow-Acting Drugs for Osteoarthritis) therapies such as chondroitin sulfate (CS)
and glucosamine (GlcN). Although several clinical trials have examined the structure-modifying effects of these
drugs1–6, the outcomes of the treatment with a combination of glucosamine and chondroitin sulfate (Glu/CS) on
knee OA progression are still under debate. The recent Glucosamine/Chondroitin Arthritis Intervention Trial
(GAIT study) suggests that the combination of glucosamine and chondroitin sulfate may be effective in the
subgroup of patients with moderate-to-severe knee pain7. In a more recent analysis by Pelletier et al., using data
from participants enrolled in the progression cohort of the OAI, there was evidence of a beneficial effect of the
Glu/CS at delaying knee OA structural progression: Participants who took Glu/CS had reduced loss of cartilage
volume over 24 months in subregions assessed with qMRI, thus supporting a disease-modifying effect of Glu/CS
that could not be identified by X-rays8. However, recent meta-analysis fuel the controversy surrounding the
efficacy of these drugs in terms of pain and structure modifications, stimulating further investigations about the
mechanistic effects of CS and GlcN9.
The effect of combined formulations of chondroitin and glucosamine has been extensively reported in several
in vitro studies10–14. Chan and collaborators demonstrated that, in bovine cartilage explants, the combination of
CS with glucosamine hydrochloride was slightly better than glucosamine alone in inhibiting both inflammatory
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matrix (ECM) metabolism remain poorly understood, and their
action on factors involved in cartilage remodelling has never been
investigated by proteomic tools.
Proteomics is being increasingly applied for the study of drug
modes of action, side-effects and toxicity, and it is also a valuable
approach for the discovery of new drug targets. In OA research, our
group exhibits a good track record employing quantitative proteo-
mics technologies for anti-OA drug screening. In 2010, we published
the first pharmacoproteomic study aimed to unravel the molecular
mechanisms driven by CS alone or in combination with GlcN sul-
fate15, which was performed by a gel-based proteomic analysis of
human articular chondrocytes (HACs) stimulated with IL-1b. In that
work, a large number of target proteins of CS and GlcN were
described, pointing out the different mechanisms of action of these
drugs. Nevertheless, in most cases both molecules synergistically
modified the chondrocyte proteome, showing a potent effect on
oxidative stress and modulation of energy production and metabolic
pathways. Furthermore, using that approach we could only evaluate
the intracellular mechanisms modulated by CS and GlcN, which are
the background for ulterior putative changes of ECM turnover. Once
the utility of proteomics for analyzing the intracellular targets of
these two drugs was proved, we decided to focus on the analysis of
the subset of chondrocyte extracellular proteins that are essential for
cartilage ECM synthesis and turnover processes. With this objective,
a quantitative profile of the chondrocyte extracellular protein
changes driven by CS both in normal and OA chondrocytes was
recently obtained by the SILAC technique16,17. These works provided
novel molecular evidences of CS properties and underlined the need
of stricter regulations regarding CS quality control. Furthermore, for
the first time, chondrocyte secretome emerged as an attractive start-
ing point for the discovery of new OA drug targets (i.e. angiogenesis)
and also for the identification of novel efficacy markers for monitor-
ing different OA treatments.
In the present work, we analyze the synergic effect of glucosamine
and chondroitin sulfate, addressing for the first time the study of
chondrocytes secretome using a gel-free approach and employing the
isobaric tags for relative and absolute quantitation (iTRAQ) meth-
odology, in order to overcome the limitations of the classical elec-
trophoresis-based methods (DIGE and SILAC). By these means, we
have performed a shotgun proteomics experiment on OA HACs
secretomes that pursued to evaluate the combined effect of CS and
GlcN on cartilage ECM biology, and to better characterize their
mechanism of action.
Results
Secretome profiling of CS- and/or GlcN-treated HACs. Superna-
tants from OA HACs, treated with CS alone or in combination with
GlcN, were collected after 48 hours of incubation for the proteomic
analysis. Samples were concentrated by filtration, cleaned up by
acetone precipitation and quantified. An aliquot of these samples
was resolved by SDS-PAGE. As revealed by silver staining (Supple-
mentary Figure S1), HAC supernatants display a medium comple-
xity. Nevertheless, we decided to carry out a two-dimensional
approach in order to achieve the greatest number of identified
proteins. A schematic workflow of this work is depicted in Fig. 1.
Firstly, equal amounts of proteins from the experimental conditions
to be compared (treated or untreated with CS and/or GlcN) were
digested with trypsin, and then the correspondent tryptic peptides
were labeled with four different iTRAQ tags. The resulting labeled
peptides were combined and separated using reversed phase LC prior
to MS analysis for the identification and relative quantification of the
corresponding proteins. Biological (n 5 3) and technical (n 5 2)
replicates were analyzed to increase the reliability of the iTRAQ
technique for relative quantitation18. A total of 186 proteins could
be identified in chondrocytes secretome after combining the results
from all the experiments (false discovery rate at 1%) with two or more
peptides with 95% confidence and total score $ 2, and quantified
(Supplementary Table S1). As expected, many of the identified
proteins were ECM components of mature cartilage or matrix
regulating factors including proteases, protease inhibitors, growth
factors, and anti-inflammatory agents. Furthermore, the iTRAQ
labeling allowed us to identify 9 unique peptides of collagen II
(COL2A1), a specific cartilage marker that was not previously
detected using the MALDI-MS approach. This might be due to the
improved MALDI ionization of the peptides that is triggered by the
iTRAQ method, and also to the independence of this technique from
newly protein synthesis rate. In fact, previous studies on chondro-
cytes using SILAC labeling failed to identify COL2A116,19,20, which
can be attributed to the very low rate of type II collagen turnover. A
higher number of COL2A1 peptides has been detected only in studies
on articular cartilage (from mouse and human origin) using a
different type of ionization source (electrospray)21–23. Considering
the global effect of the pharmacological treatment in altering
chondrocytes secretome profile, we found thirty-six proteins
significantly modulated (pvalue # 0.05) in OA treated cells when
compared to untreated ones (basal condition): 32 were increased and
4 were decreased (Table 1). Among them, CS alone altered the
expression of twenty-eight HACs secreted proteins, while GlcN
alone modulated only twelve of these proteins. Data analysis
resulted more informative when we compared the effect of the
combined formulation with each compound separately (Table 2).
We found 18 proteins upregulated and only one, VIM, down-
regulated when we analyzed GlcN alone or in combination with
CS (Table 2A). Among them we found thrombospondin-1 (THBS1
or TSP1), a protein recently described by our group as potential new
target for OA treatment16. GlcN alone is unable to alter THBS1
expression level, but when combined with CS a strong increase is
observed (ratio 5 3,281; pvalue 5 0,0001). On the other hand, when
we focused on CS alone or in combination with GlcN, only 3 proteins
were found as significantly modulated: VIM and FN1 increased and
TGFBI decreased (Table 2B).
Bioinformatic analysis of differentially expressed proteins. The
STRING database was searched for protein interaction analyses in
order to elucidate the effect of CS alone and in combination with
GlcN. As shown in Figure 2, almost all (28) of the altered proteins
interact with each other to constitute a big network. These proteins
are involved in three main GO biological processes characteristic of
connective tissue such as cell adhesion, cartilage development, and
ECM organization. Among them, proteins such as collagen VI, XII,
and tenascin showed increased release to the medium following all
three treatments (Fig. 3A). The Pike tool was used to assign the
cellular compartment of the identified proteins24. As shown in
Fig. 3B, 60% of them are classically annotated as secreted proteins.
Verification of the modulation of THBS1 and TGFBI in NvsOA
HACs. Taking into account previous proteomics results by our
group16,20, we focused in particular on two proteins identified in
this study: THBS1 and TGFBI. In our previous studies we could
verify a significant modulation in the secretion of these proteins in
IL1b-stimulated HACs. In the present work, Real Time-PCR assays
demonstrated that THBS1 gene expression levels are decreased (ratio
5 0,45; pvalue # 0,05), while those of TGFBI are increased (ratio 5
1,98; pvalue # 0,05) in OA HACs compared to normal cells (Fig. 4).
GlcN alone does not alter the expression of either THBS1 or TGFBI,
whereas CS alone upregulates both genes (Table 1). Finally, CS 1
GlcN upregulates THBS1 compared to untreated cells (Table 1) and
dowregulates TGFBI compared to CS-treated cells (Table 2B).
Modulation of THBS1 by CS. In our previous studies we observed
an increase of THBS1 or TSP1 (an angiogenesis inhibitor) driven by
CS both in absence of IL1b stimulation, in OA chondrocytes17, and
also in presence of this potent inflammatory cytokine in N cells16. In
www.nature.com/scientificreports
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this case, as shown in Fig. 5, we detected a remarkable increase of
thrombospondin 1 as a consequence of the cell treatment with CS
alone (both at mRNA and protein level) and in combination with
GlcN (only at protein level). Moreover, if we compared the effect of
the combined formulation with that of GlcN alone, we observed a
statistically significant increase in THBS1 protein expression level
(Table 2A, Fig. 5B).
Discussion
We have performed a gel-free quantitative proteomics experiment
for the analysis of secretomes (cell conditioned media) from CS and/
or GlcN-treated OA HACs. This study has allowed us to generate a
quantitative profile of chondrocyte extracellular protein changes dri-
ven by different CS formulations (simple and combined with GlcN).
The strategy used is based on the differential labeling of peptides with
iTRAQ reagents prior to their separation and analysis by multidi-
mensional LC coupled to MS (Fig. 1). A previous analog study by our
group described intracellular changes driven by CS and GlcN using a
classical proteomic approach by 2DE15. 2DE is a powerful proteomic
profiling technique for both protein identification and quantitation;
however this traditional method showed some limitations in term of
reproducibility. Furthermore, the 2DE platform fails to detect
proteins with extreme pH values (greatly represented in cartilage
by the high density and anionic nature of proteoglycans), high or
low molecular weight, proteins present in low copy numbers, and
those with hydrophobic domains. In this sense, LC-MS/MS analysis
overlaps these drawbacks, which are particularly important given the
especial features of HACs, which synthesize and secrete a variety of
highly anionic compounds (glycosaminoglycans) and a few abund-
ant proteins (mainly collagens and proteoglycans) that hamper the
performance of 2-DE-based approaches. Therefore, we recently
developed an alternative method based on metabolic labeling
(SILAC) for the quantitative analysis of chondrocytes proteome
and secretome16,17,20, and also for the analysis of human bone marrow
mesenchymal stem cells proteome during chondrogenic differenti-
ation25. In this case, the main disadvantage is the limited number of
conditions that can be compared simultaneously (usually two), and
also the large culture time needed to obtain the fully labeled cell
populations that are necessary for quantification. For all these rea-
sons, LC-MS techniques have begun to exercise their dominance in
the OA research field. Among these strategies, the use of iTRAQ
protein tags significantly reduce sample-to-sample and time-point
variation26, improves the ionization and subsequent analysis of pep-
tides and finally allows the quantification of proteins in samples from
Figure 1 | Schematic workflow.
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different subjects, stages of disease or treatment conditions (up to 8)
in a rapid and reproducible way.
The present study demonstrates the different effects of the simple
and the combined administration of CS on OA HACs. CS alone
increased the expression level of 24 proteins and decreased 4
(Tab. 1). Interestingly, the four decreased proteins are intracellular:
two with a structural function (VIM, MSN), a glycolytic enzyme
(PKM2), and a chaperone (HSP90B). Both vimentin and heat shock
protein 90 beta are described in literature as OA-related proteins, as
their protein expression levels are altered in OA chondrocytes27,28.
Increased vimentin fragments were observed in a rat OA model29 and
also in human OA cartilage30, and this correlates with a disrupted
vimentin network. Here, we found that VIM is decreased by CS
treatment (Table 1). Therefore, we hypothesize that CS could be
effective in restoring a proper cytoskeleton network in OA-affected
chondrocytes. On the other hand, a previous proteomic analysis
performed by our group revealed an increase of the b subunit of
the chaperone Hsp90 in diseased cells28. Many metabolic processes
contributing to age-related changes in cartilage ECM are influenced
by known roles of Hsp90b, such as COL2A1 and MMP-13 express-
ion and NO synthesis31,32. Our result suggests that the well documen-
ted anabolic, anti-catabolic and anti-inflammatory properties of CS
should be partially mediated by the Hsp90 inhibition observed in CS-
treated chondrocytes10–12,33,34. However, further studies are needed to
determine whether Hsp90b could serve as a therapeutic target of CS
for reducing cartilage degradation in OA.
In OA HACs treated with GlcN alone, all of the modulated pro-
teins were increased when compared to the untreated cells (Tab. 1).
Generally, the increase observed is lower than the one observed with
CS for the same proteins (except for ANXA5). Two proteins
(CHI3L1 and PENK) were modulated only by GlcN alone or com-
bined with CS, and one was found to be positively modulated only by
GlcN alone (LDHA). Interestingly, in our first pharamacoproteomic
study15, all the proteins modulated by glucosamine sulfate (GS)
related to energy production were decreased; while in the case of
GlcN?HCl we found a slight increase (ratio 5 1,888; pvalue 5
0,0272) of this glycolytic enzyme. This difference could be deter-
mined by the different GlcN formulation employed, but probably
also by the different cellular compartment analyzed.
Similar to the GAIT study7, many clinical trials tested CS together
with glucosamine2,35,36. The results suggest that both components
may enhance each other’s efficacy. This synergistic effect was also
proposed by various in vivo and in vitro studies10–13,37–39. As reviewed
in recent works40–42, the mechanism of action of CS differs in several
aspects from that of GlcN. In vivo and in vitro experiments have
demonstrated that CS reaches the joint, and distributes into the
Table 1 | Secreted proteins identified by iTRAQ and LC-MS analysis as modulated by different treatments in OA HACs
Score % Cov95 Accession# Name Symbol Peptides CS$ GlcN$ CS 1 GlcN$
7,33 5,8 Q9UHI8 A disintegrin and metalloproteinase with
thrombospondin motifs 1
ADAMTS1 5 7,87 1,44* 7,18
31,18 6,8 P16112 Aggrecan core protein ACAN 18 7,31 2,88* 9,29
27,8 45,6 P01011 Alpha-1-antichymotrypsin SERPINA3 18 1,50 1,47 1,54
17,67 30,4 P07355 Annexin A2 ANXA2 10 2,31 2,38 2,13
10,17 22,8 P08758 Annexin A5 ANXA5 6 2,33 2,70 2,15*
31,74 47,3 P21810 Biglycan BGN 38 2,11 1,26* 2,25
54,29 40,6 P49747 Cartilage oligomeric matrix protein COMP 60 2,51* 1,89* 3,25
96,46 73,1 P36222 Chitinase-3-like protein 1 CHI3L1 236 3,38* 3,19 4,33
18,32 10,2 Q76M96 Coiled-coil domain-containing protein 80 CCDC80 9 2,63 1,61 2,40
19,37 9,9 P20908 Collagen alpha-1(V) chain COL5A1 17 1,72 1,17* 1,96
45,04 28,6 P12109 Collagen alpha-1(VI) chain COL6A1 55 2,68 1,53* 1,96
158,4 35,9 Q99715 Collagen alpha-1(XII) chain COL12A1 108 5,50 4,17 6,55
129,14 68,2 P08123 Collagen alpha-2(I) chain COL1A2 180 2,15 1,14* 2,01
80,88 16,9 P12111 Collagen alpha-3(VI) chain COL6A3 49 5,15 2,70 3,91
7,59 12,6 P29279 Connective tissue growth factor CTGF 4 2,54 1,16* 2,40
13,63 21,8 Q06828 Fibromodulin FMOD 11 2,19 1,47* 1,71
150,04 40,6 P02751 Fibronectin FN1 147 0,86* 2,07* 2,58
55,85 64,3 P07093 Glia-derived nexin SERPINE2 79 6,98 2,44 7,87
5,12 4,1 P08238 Heat shock protein HSP 90-beta HSP90B 3 0,28 0,54* 0,50*
19,69 35,6 P10915 Hyaluronan and proteoglycan link protein 1 HAPLN1 14 4,70 1,44* 4,88
18,38 25,6 P00338 L-lactate dehydrogenase A chain LDHA 13 1,54* 1,89 1,67*
43,27 43,5 P51884 Lumican LUM 100 2,29* 1,56* 1,91
16,35 30,9 P20774 Mimecan OGN 15 1,92 1,05* 1,47*
15,89 13 P26038 Moesin MSN 10 0,52 1,14* 0,95*
7,86 13,4 P26022 Pentraxin-related protein PTX3 PTX3 7 3,77 2,65* 4,06
19,36 20 P05155 Plasma protease C1 inhibitor SERPING1 12 1,63 1,39* 1,64
15,15 25,2 Q15113 Procollagen C-endopeptidase enhancer 1 PCOLCE 10 1,82 1,29* 1,82*
13,57 35,2 P01210 Proenkephalin-A PENK 8 1,39* 1,49 1,54
23,69 26,4 P14618 Pyruvate kinase isozymes M1/M2 PKM2 12 0,53 0,89* 0,63
26,09 33,5 P08254 Stromelysin-1 MMP3 19 1,82 1,41 1,54
22,05 11,3 Q7Z7G0 Target of Nesh-SH3 ABI3BP 11 2,03 1,19* 2,56
88,43 28 P24821 Tenascin TNC 61 3,60 2,44 3,66
19,55 12 P07996 Thrombospondin-1 THBS1 15 4,09 1,03* 3,37
59,59 57,4 Q15582 Transforming growth factor-beta-induced
protein ig-h3
TGFBI 63 2,58 1,82* 1,20*
15,2 17,5 P19320 Vascular cell adhesion protein 1 VCAM1 11 3,10 1,14* 2,83
51,29 53,7 P08670 Vimentin VIM 40 0,68 1,57* 1,02*
#Protein accession number according to SwissProt and TrEMBL databases.
$Average iTRAQ ratios that represent the relative protein abundance in treated (CS, chondroitin sulfate; GlcN, glucosamine hydrochloride) vs untreated cells, calculated by Protein Pilot 3.0 software. A
p-value # 0.05 was accepted.
*Not statistically significant change.
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cartilage and subchondral layers43,44. However, being a large mole-
cule, CS does not penetrate into the cells45, and so elicits its anti-
inflammatory effect by engaging chondrocytes membrane receptors,
e.g. CD44, TLR4, and ICAM1. In fact there is evidence that CS
directly and/or indirectly modulates CD44 anti-inflammatory
effects. CS engages CD44 and is internalized46,47. By binding to this
receptor, CS could modulate transcriptional factors such as NF-kB
thus blocking pro-inflammatory signaling pathways with down-
regulation of target genes, such as ADAMTS, MMPs, IL-1b, and
iNOS48. Campo et al. had also demonstrated that CS could act on
the toll-like receptor (TLR)-4 to inhibit the inflammatory cytokines,
MyD88 and tumour necrosis factor (TNF) receptor associated factor
(TRAF)-6, through the inhibition of nuclear factor (NF)-kB activa-
tion49. CS maintains the integrity of the cartilage ECM by two ways:
reducing the expression of MMP1, MMP3, MMP13, ADAMTS1 and
ADAMTS2, hence preventing the degradation of collagen, proteo-
glycans and aggrecan48; engaging integrins and increasing TGF-b1
expression that fosters the synthesis of hyaluronic acid and collagen
II41. In addition, CS-containing proteoglycans play important roles in
growth factor signaling in vivo, particularly during chondrogenesis50.
Due to its highly negative charge, CS is able to interact electrostati-
cally with positively charged growth factors such as TGFb151. This
ability to sequester growth factors should be exploited as drug deliv-
ery vehicles for controlled delivery and release, especially for repair of
cartilaginous tissues52. On the other hand, GlcN penetrates into cells
by means of glucose transporters (GLUTs). Once taken up by cells,
Table 2 | In table 2A the average iTRAQ ratios represent the relative protein abundance in cells treated with the combined formulation vs
glucosamine (GlcN)-treated cells. In table 2B, the ratios represent the effect of the combined formulation vs chondroitin sulfate (CS) alone
A)
Accession# Name Symbol CS 1 GlcN:GlcN Pvalue
Q9UHI8 A disintegrin and metalloproteinase with thrombospondin motifs 1 ADAMTS1 5,50 0,038
P16112 Aggrecan core protein ACAN 3,37 0,000
P21810 Biglycan BGN 1,80 0,003
P49747 Cartilage oligomeric matrix protein COMP 1,74 0,035
Q76M96 Coiled-coil domain-containing protein 80 CCDC80 1,47 0,023
P02452 Collagen alpha-1(I) chain COL1A1 1,51 0,055
P02461 Collagen alpha-1(III) chain COL3A1 1,71 0,056
P20908 Collagen alpha-1(V) chain COL5A1 1,66 0,020
Q99715 Collagen alpha-1(XII) chain COL12A1 1,63 0,001
P08123 Collagen alpha-2(I) chain COL1A2 1,75 0,008
P12111 Collagen alpha-3(VI) chain COL6A3 1,45 0,026
P07093 Glia-derived nexin SERPINE2 3,44 0,000
P10915 Hyaluronan and proteoglycan link protein 1 HAPLN1 3,63 0,003
Q99985 Semaphorin-3C SEMA3C 3,50 0,019
Q7Z7G0 Target of Nesh-SH3 ABI3BP 2,17 0,001
P24821 Tenascin TNC 1,50 0,000
P07996 Thrombospondin-1 THBS1 3,28 0,000
P19320 Vascular cell adhesion protein 1 VCAM1 2,56 0,009
P08670 Vimentin VIM 0,63 0,001
B)
Accession# Name Symbol CS 1 GlcN:CS Pvalue
P02751 Fibronectin FN1 2,94 0,000
Q15582 Transforming growth factor-beta-induced protein ig-h3 TGFBI 0,45 0,015
P08670 Vimentin VIM 1,46 0,002
#Protein accession number according to SwissProt and TrEMBL databases.
Figure 2 | Protein-protein interaction network. The STRING database was searched for protein interaction analyses in order to elucidate the effect of CS
alone and in combination with GlcN. As shown in this Figure, almost all (28) of the altered proteins interact with each other to constitute a big network.
These proteins are involved in three main GO biological processes: (A) cell adhesion, (B) cartilage development, (C) and ECM organization.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5069 | DOI: 10.1038/srep05069 5
exogenous GlcN is phosphorylated into GlcN-6-phosphate, which
subsequently enters into the hexosamine biosynthetic pathway to
generate UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc
is a substrate for the synthesis of proteoglycans, glycolipids, and
glycoproteins but also for protein acylation through O-linked
GlcNAcylation (O-GlcNAc)53. Proteins can be modified reversibly
at serine or threonine residues by attachment of a GlcNAc molecule.
As suggested by Scotto D’Abusco et al. the effects of GlcN could
derive, at least in part, from its capacity to O-GlcNAcylate proteins,
primarily kinases (JNK, p38 and IKKa)54,55. In the case of chondro-
cytes treated with GlcN, this protein modification competes with
phosphorylation by utilizing the same amino acidic sites and, as a
consequence, GlcN reduces NF-kB nuclear translocation and abro-
gates the transcription of proteolytic and pro-inflammatory target
genes. In our first pharmacoproteomic study we evaluated the
potency of the use of CS in combination with GlcN15. These com-
pounds produced different patterns of protein modification when
tested alone or in combination. However, in most cases a synergistic
effect was demonstrated when cells were exposed to both com-
pounds, implying a potent effect on oxidative stress as indicated
by the modulation of superoxide dismutase. Finally we can conclude
that the differences in their mechanism of action could explain why
the combination of CS and GlcN should be more effective than each
individual drug supporting the use of the combined formulation. In
the present study we focused on the subset of secreted proteins in
order to identify putative novel biomarkers that would be easily
detectable in the bloodstream of treated patients and therefore useful
to discriminate responders and non-responders. The Venn diagram
showed in Fig. 3A depicts the overlap of proteins modulated in OA
chondrocytes by each treatment, and is quite similar to that prev-
iously obtained in normal HACs stimulated with IL1b. In the case of
CS, we observed a 62% of similarity with the combined treatment,
while in the case of GlcN only a 33% was detected. A slight syn-
ergistic effect was noticed for some ECM components (ACAN,
CHI3L1, COL5A1, and COL12A1). In other cases, a statistically
significant modulation was seen only when CS and GlcN were
employed together (COMP, FN1, and LUM).
As concluding remarks, our findings confirm in OA HACs the
synergistic chondroprotective effect of chondroitin sulfate and glu-
cosamine hydrochloride that was previously described by our group
in normal cells. In fact, despite having employed in such studies
different proteomic strategies based on 2DE, DIGE and SILAC, the
modulation of several proteins (like VIM, PKM2, THBS1) in CS-
treated chondrocytes has been observed also in this study (Table 3).
Moreover, the iTRAQ approach exhibits the advantages for the rela-
tive quantification of HACs secreted proteins. This is especially use-
ful to focus on cartilage ECM proteins, which have particular
importance for their role in proper tissue maintenance. To our know-
ledge, this is the first time that COL2A1 is identified by MALDI-MS
in chondrocytes secretome. If the presence of this protein into the
conditioned medium represents new matrix synthesis, matrix degra-
dation, or passive loss of components from the chondrocytes needs to
be investigated. Furthermore, the subset of OA chondrocyte extra-
cellular proteins has been successfully evaluated for the search of
non-invasive OA biomarkers. In fact, the main goal of this study,
in addition to focus on the evaluation of the combined formulation, is
also to serve as novel source for OA biomarker discovery. Several
proteins have emerged as putative candidate biomarkers and, hope-
fully, the negative correlation between THBS1 and TGFBI expression
that we have encountered can be exploited in the next future for
screening the presence of OA disease or monitoring therapeutic
effectiveness in clinical samples. Especially THBS1, which is down-
regulated in OA chondrocytes and then upregulated after pharmaco-
logical treatment, could be a good standard for the outcome
measures of clinical trials assisting data interpretation and enabling
rigorous comparisons between different studies. However, further
investigations on biological fluids are necessary to assess its biomar-
ker usefulness.
Methods
Cartilage procurement and processing. Cartilage obtained from three OA patients
(73, 78 and 84 years old) undergoing joint replacement was provided by the Tissue
Bank and the Autopsy Service at CHU A Coruña for the pharmacoproteomic
analysis. The study was approved by the local Ethics Committee. Articular
chondrocytes were isolated from human cartilages as previously described15,56.
Briefly, once cartilage surfaces were rinsed with saline, scalpels were used to cut
parallel sections 5 mm apart, vertically from the cartilage surface onto the
subchondral bone. These cartilage strips were then cut-off from the bone, and the
tissue was incubated with trypsin at 37uC for 10 min. After removing trypsin solution,
the cartilage slices were treated for 12–16 h with type IV clostridial collagenase in
DMEM with 10% FBS in order to release cartilage cells.
Chondrocytes culture and pharmacological treatment. Chondrocytes were
recovered and cultured in DMEM supplemented with 100 U/mL penicillin, 100 mg/
mL streptomycin, 1% glutamine, and 10% FBS. Cells were seeded onto 100 mm
culture plates for proteomic studies or 6-well plates for total RNA extraction. The cells
were incubated at 37uC in a humidified gas mixture containing 5% CO2 balanced
with air. Chondrocytes were used at weeks 2–3 in primary culture, after making them
Figure 3 | Data mining. (A) Venn diagram depicting proteins modulated
similarly and differently by CS-, GlcN- and CS 1 GlcN-treatment in OA
HACs. Proteins in the green circle are modulated by CS, proteins in the
violet circle are modulated by GlcN, and proteins in the blue circle are
modulated by the combined treatment. All proteins are upregulated except
VIM, MSN, HSP90AB1 and PKM2. (B) Component pie charts indicating
the cellular localization of those proteins identified in the HACs secretome,
according to Gene Ontology annotation.
www.nature.com/scientificreports
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quiescent by incubation in a medium containing 0.5% FBS for 24 h. Finally, cells were
cultured for 48 hours in serum free medium containing chondroitin sulfate (CS) and/
or glucosamine hydrochloride (GlcN or GH). Both molecules were pharmacological
grade and were provided by Bioiberica S.A. (Barcelona, Spain). CS was from bovine
origin, with a CS content of 99.9% and a molecular weight of 15.12 kDa. Other
characteristics (viscosity, sulfation sites, etc.) have been previously detailed
elsewhere17,57. CS and GlcN concentrations (both 200 mg/mL) were optimized for the
proteomic studies in accordance with previous results by our group and literature
data15,20 where a very wide range of both glucosamine and chondroitin sulfate have
been used on different cell types and tissues. These concentrations are also in
accordance with those tested in the standardization step of our proteomic analysis
(CS from 20 to 200 mg/ml and GlcN from 1 to 10 mM).
Processing of conditioned media for iTRAQ labeling. Conditioned media (CM)
obtained from 3 different samples were analyzed independently. CM were collected,
centrifuged and filtered using a 0.2 mm filter to ensure removal of any dead cells.
Supernatant of each dish (6 mL) was concentrated to a final volume of 250 ml with
Amicon ultrafiltration units (5 kDa MWCO, Millipore, Billerica, MA, USA) and then
cleaned up by acetone precipitation. Protein pellets were dried in air and then
resuspended in 25 ml Dissolution Buffer. Protein concentrations were determined by
Bradford assay (Sigma-Aldrich, St. Louis, MO, USA). Equal amounts of chondrocyte
secreted proteins (20 mg) from each condition were reduced, alkylated, and digested
with trypsin. Then iTRAQ labeling was performed according to the supplier’s
instructions (ABSciex, Foster City, CA, USA). The samples were labeled as follows:
controls, 114; CS, 115; GH, 116; CS 1 GH, 117. iTRAQ-labeled peptides were mixed
and desalted using reversed phase columns (Pierce C18 Spin Columns, Thermo
Fisher Scientific, Rockford, IL, USA) prior to liquid chromatography coupled to mass
spectrometry (LC-MS) analysis (Fig. 1).
LC-MS analysis. The peptide mixture was firstly separated by off-line reversed-phase
liquid chromatography (RP-LC) at basic pH (pH 5 10) to lower its complexity. The
separation was performed on a HP 1200 system (Agilent Technologies, Santa Clara,
CA, USA) employing a C18 reversed-phase column (Zorbax extend C18, 100 3
2.1 mm id, 3.5 mm, 300 Å; Agilent). The flow rate used was 0.2 mL/minute and the
gradient was as in Suppl. Fig. S2. The chromatogram was produced using a UV
Detector at 214 nm. Several fractions were pooled post-collection (FC203B fraction
collector, Gilson, Middleton, WI, USA) based on the peak intensity of the UV trace,
yielding a total of 26 samples per LC run. Each fraction was dried in a vacuum
concentrator and stored at 220uC for the next step of analysis. The dried peptide
fractions were dissolved in 0.1% trifluoroacetic acid (TFA) and 2% acetonitrile; 5 mL
of this sample were injected onto a capillary trap column (0.5 3 2 mm, Michrom
Bioresources, Auburn, CA, USA) at a flow rate of 15 ml/minute. Peptides were
desalted for 10 minutes and loaded onto a C18 column (Integrafit C18, ProteopepTM
II, 75 mm id, 10.2 cm, 5 mm, 300 Å; New Objective, Woburn, MA, USA) at a constant
flow rate of 350 nl/minute to perform the separation. Then peptides were separated
using linearly increasing concentration of acetonitrile in buffer B. The RP analytical
Figure 4 | Verification of the modulation of TGFBI and THBS1 in NvsOA HACs by Real-Time PCR. A significant increase (pvalue # 0,05) in the gene
expression of TGFBI (or BIGH3) and a decrease of THBS1 (or TSP1) were detected in OA (n 5 7) HACs compared to normal (n 5 6) cells.
Results are expressed as the mean 6 standard error.
Figure 5 | Thrombospondin-1 (THBS1 or TSP1) is increased by CS alone and in combination with GH. Overexpression values of TSP1 were determined
by real-time PCR (A) and Western blot analysis (B) of human articular chondrocytes from 3 OA donors. Results are expressed as mean 6 SEM of 3
independent experiments. A representative image of Western blot is shown. *p , 0.05: chondroitin sulfate (CS)-treated group was significantly different
from unstimulated group (CTL) both at mRNA and protein level, while the combination of CS 1 GH (glucosamine hydrochloride) was effective only at
protein level. &p , 0.05: GH-treated group was significantly different from CS 1 GH group at protein level.
www.nature.com/scientificreports
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column eluent was spotted onto a matrix-assisted laser desorption/ionization
(MALDI) sample plate using the Sun Collect MALDI Spotter/Micro Collector
(SunChrom Wissenschaftliche Geräte GmbH, Germany) and analyzed by a 4800
mass spectrometer (AB Sciex). After the screening of all LC-MALDI sample positions
in MS positive reflector mode, the fragmentation of automatically selected precursors
was performed to generate fragment ions that provided sequence information for the
peptide and reporter ions. MS and MS/MS parameters have been detailed
elsewhere20,26.
Data analysis. Protein identification and quantification were carried out using
ProteinPilotTM software v.4.0 (ABSciex). Each MS/MS spectrum was searched in the
Uniprot/Swissprot database (downloaded in May 2012) for Homo sapiens. Search
parameters within ProteinPilot were set with trypsin cleavage specificity; methyl
methanethiosulfate (MMTS) modified cysteine as fixed modifications; biological
modification ‘‘ID focus’’ settings, and a protein minimum confidence score of 95%.
Thus, the identity of the protein from the analyzed peptide was confirmed, and the
ratios of the peak areas of iTRAQ reporter ions were used to compare the relative
abundance of the protein identified in the sample. Only proteins identified with at
least 95% confidence, or a Prot Score (protein confidence measure) of at least 1.3 were
reported (Supplementary Table S1). Data were normalized for loading error by bias
and the background correction was calculated using the Pro GroupTM algorithm
(ABSciex). To determine the cutoff value for significant fold changes, coefficient of
variation and cumulative frequency were calculated for the common proteins
employing the R statistical package58. Using this tool, we considered statistically
significant only those changes with a p value # 0.05 and a ratio $ 1.4 (or #0.7). The
results obtained from ProteinPilot were exported to Microsoft Excel for further
analyses.
Real-time PCR assays. Total RNA was isolated from OA and N HACs (5 3 105 per
well) using Trizol Reagent (Invitrogen), following the manufacturer’s instructions.
cDNA was synthesized from 1 mg total RNA, using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, Basel, Switzerland) in accordance with the
manufacturer’s instructions, and analyzed by quantitative real-time PCR.
Quantitative real-time PCR assay was performed in the LightCycler 480 instrument
(Roche) using 96-well plates. Primers for THBS1, TGFBI and the housekeeping genes,
HPRT1 and RPLP0, were designed using the Universal Probe Library tool from the
Roche website (http://www.roche-applied-science.com). Primer sequences were as
follows: THBS1 forward, 59-GCTGCACTGAGTGTCACTGTC-39; THBS1 reverse,
59-TCAGGAACTGTGGCATTGG-39; TGFBI forward, 59- CGAGTGCTGTCC-
TGGATATG-39; TGFBI reverse, 59- CCCAGGGTCTCGTAAAGGTT-39; HPRT1
forward, 59-TGACCTTGATTTATTTTGCATACC-39; HPRT1 reverse, 59-CGAG-
CAAGACGTTCAGTCCT-39; RPLP0 forward, 59-TCTACAACCCTGAAG-
TGCTTGAT-39, PRPL0 reverse 59-CAATCTGCAGACAGACACTGG-39. The
results were analyzed using the LightCycler 480 software release 1.5.0 (Roche).
Western blot analysis. Western blot analyses were performed utilizing standard
procedures. Chondrocytes from 3 OA donors different from those selected for the
proteomics strategy were used. Briefly, 20 mg of secreted proteins were loaded and
resolved using 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The
separated proteins were then transferred to polyvinylidene fluoride (PVDF)
membranes (Immobilon P, Millipore Co., Bedford, MA, USA) by electro-blotting and
probed with specific antibodies against THBS1 or TSP1 (Santa Cruz).
Immunoreactive bands were detected by chemiluminescence using corresponding
horseradish peroxidase (HRP)-conjugated secondary antibodies and enhanced
chemiluminescence (ECL) detection reagents (GE Healthcare), then digitized using
the LAS 3000 image analyzer. Equivalent loadings were verified by Ponceau Red
(Sigma) staining after transference (data not shown). Quantitative changes in band
intensities were evaluated using ImageQuant 5.2 software (GE Healthcare).
Statistical analysis. The statistical significance of the differences between mean
values was determined using the two-tailed t-test, accepting p # 0.05 to be significant.
In the proteomic analysis, normalization tools and statistical package from
ProteinPilot software were employed. Searches against a concatenated database
containing both forward and reversed sequences allowed the false discovery rate
(FDR) to be kept at 1%. Proteomics System Performance Evaluation Pipeline
(PSPEP) software was used independently to calculate false discovery rates. Where
appropriate, results are expressed as the mean 6 standard error.
1. Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D. & Reginster, J. Y. Long-
term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on
osteoarthritis progression prevention, a two-year, randomized, double-blind,
placebo-controlled trial. Arthritis Rheum 60, 524–533 (2009).
2. Bruyere, O. & Reginster, J. Y. Glucosamine and chondroitin sulfate as therapeutic
agents for knee and hip osteoarthritis. Drugs Aging 24, 573–580 (2007).
3. Pavelka, K. et al. Glucosamine sulfate use and delay of progression of knee
osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.
Arch Intern Med 162, 2113–2123 (2002).
4. Reginster, J. Y. et al. Long-term effects of glucosamine sulphate on osteoarthritis
progression: a randomised, placebo-controlled clinical trial. Lancet 357, 251–256
(2001).
5. Rovati, L. C., Girolami, F. & Persiani, S. Crystalline glucosamine sulfate in the
management of knee osteoarthritis: efficacy, safety, and pharmacokinetic
properties. Ther Adv Musculoskelet Dis 4, 167–180 (2012).
6. Michel, B. A. et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a
randomized, controlled trial. Arthritis Rheum 52, 779–786 (2005).
7. Clegg, D. O. et al. Glucosamine, chondroitin sulfate, and the two in combination
for painful knee osteoarthritis. N Engl J Med 354, 795–808 (2006).
8. Martel-Pelletier, J. et al. First-line analysis of the effects of treatment on
progression of structural changes in knee osteoarthritis over 24 months: data from
the osteoarthritis initiative progression cohort. Ann Rheum Dis 2013-203906, doi:
10.1136/annrheumdis-2013-203906 (2013).
9. Zhang, W. et al. OARSI recommendations for the management of hip and knee
osteoarthritis: part III: Changes in evidence following systematic cumulative
update of research published through January 2009. Osteoarthritis Cartilage 18,
476–499 (2010).
10. Chan, P. S., Caron, J. P. & Orth, M. W. Effect of glucosamine and chondroitin
sulfate on regulation of gene expression of proteolytic enzymes and their
inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J
Vet Res 66, 1870–1876 (2005).
11. Chan, P. S., Caron, J. P., Rosa, G. J. & Orth, M. W. Glucosamine and chondroitin
sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin
E(2) in articular cartilage explants. Osteoarthritis Cartilage 13, 387–394 (2005).
12. Chan, P. S., Caron, J. P. & Orth, M. W. Short-term gene expression changes in
cartilage explants stimulated with interleukin beta plus glucosamine and
chondroitin sulfate. J Rheumatol 33, 1329–1340 (2006).
13. Chan, P. S., Caron, J. P. & Orth, M. W. Effects of glucosamine and chondroitin
sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet
Res 68, 709–715 (2007).
14. Tat, S. K. et al. Chondroitin and glucosamine sulfate in combination decrease the
pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a
basic science study. Arthritis Res Ther 9, R117 (2007).
15. Calamia, V. et al. Pharmacoproteomic study of the effects of chondroitin and
glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 12, R138
(2010).
16. Calamia, V. et al. Secretome analysis of chondroitin sulfate-treated chondrocytes
reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties.
Arthritis Res Ther 14, R202 (2012).
17. Calamia, V. et al. Pharmacoproteomic study of three different chondroitin sulfate
compounds on intracellular and extracellular human chondrocyte proteomes.
Mol Cell Proteomics 11, M111.013417 (2012).
18. Gan, C. S., Chong, P. K., Pham, T. K. & Wright, P. C. Technical, experimental, and
biological variations in isobaric tags for relative and absolute quantitation
(iTRAQ). J Proteome Res 6, 821–827 (2007).
19. Polacek, M., Bruun, J. A., Elvenes, J., Figenschau, Y. & Martinez, I. The secretory
profiles of cultured human articular chondrocytes and mesenchymal stem cells:
implications for autologous cell transplantation strategies. Cell Transplant 20,
1381–1393 (2011).
20. Calamia, V. et al. Metabolic labeling of chondrocytes for the quantitative analysis
of the interleukin-1-beta-mediated modulation of their intracellular and
extracellular proteomes. J Proteome Res 10, 3701–3711 (2011).
21. Wilson, R. et al. Comprehensive profiling of cartilage extracellular matrix
formation and maturation using sequential extraction and label-free quantitative
proteomics. Mol Cell Proteomics 9, 1296–1313 (2010).
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